Phosphodiesterase type 3 and type 4 (PDE3 and PDE4)

Phosphodiesterase type 3 (PDE3) and type 4 (PDE4) are members of the cyclic nucleotide phosphodiesterase superfamily, enzymes that hydrolyze the second messengers cAMP and/or cGMP to their inactive forms[1][3][4]. PDE3 is a cGMP-inhibited, cAMP-specific phosphodiesterase highly expressed in cardiac muscle, vascular smooth muscle, and platelets, where it regulates contractility and aggregation[1]. PDE3 inhibitors are used to enhance cardiac contractility and produce vasodilation but carry risks of arrhythmias and increased mortality in long-term use[1]. PDE4 is a cAMP-specific phosphodiesterase predominantly expressed in inflammatory cells and the brain; it is involved in inflammatory and cognitive processes, and PDE4 inhibitors are approved for diseases such as COPD and psoriatic arthritis[2][4]. Both enzyme classes are important therapeutic targets for diseases related to abnormal cAMP/cGMP signaling.

Other names

PDE3 (Phosphodiesterase type 3)PDE4 (Phosphodiesterase type 4)cAMP phosphodiesterase family

Inhibition of PDE3: Increases cAMP (and somewhat cGMP) levels, leading to positive inotropic and vasodilatory effects Inhibition of PDE4: Prevents cAMP degradation, leading to anti-inflammatory effects by modulating immune cell function and reducing cytokine production